Anzeige
Mehr »
Freitag, 10.10.2025 - Börsentäglich über 12.000 News
Kursrakete 2025: CiTech präsentiert sich u.a. mit DroneShield neben Palantir & Rheinmetall - welche News sind zu erwarten?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40M9J | ISIN: US83558L3033 | Ticker-Symbol: O8Z
Lang & Schwarz
09.10.25 | 12:48
2,480 Euro
-100,00 % -2,480
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SONOMA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SONOMA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,4402,52009.10.

Aktuelle News zur SONOMA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoSonoma Pharmaceuticals, Inc. - 8-K, Current Report3
DiSonoma Pharmaceuticals registers HOCl facial spray under U.S. cosmetics law6
DiSonoma Pharmaceuticals registers under FDA's cosmetics act3
DiSonoma Pharmaceuticals: FDA-Registrierung ebnet Weg in US-Kosmetikmarkt4
DiSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA210BOULDER, COLORADO / ACCESS Newswire / October 7, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized...
► Artikel lesen
SONOMA PHARMACEUTICALS Aktie jetzt für 0€ handeln
26.09.Sonoma Pharma schließt 'At-the-Market'-Verkaufsvereinbarung über bis zu 2,07 Mio. US-Dollar ab2
26.09.Sonoma Pharmaceuticals, Inc. - 8-K, Current Report1
25.09.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025368BOULDER, COLORADO / ACCESS Newswire / September 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized...
► Artikel lesen
29.08.Aktionäre von Sonoma Pharmaceuticals stimmen allen Anträgen auf der Hauptversammlung zu8
29.08.Sonoma Pharmaceuticals, Inc. - 8-K, Current Report3
26.08.Sonoma Pharmaceuticals, Inc.: National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced287BOULDER, CO / ACCESS Newswire / August 26, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
14.08.Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences616BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over...
► Artikel lesen
14.08.Sonoma Pharmaceuticals stock soars after diaper rash product hits Walmart10
14.08.Sonoma Pharma: Aktie verdoppelt sich nach Produkteinführung bei Walmart10
13.08.Sonoma Pharmaceuticals launches diaper rash product in major US retailers16
13.08.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains366BOULDER, CO / ACCESS Newswire / August 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous...
► Artikel lesen
08.08.Sonoma Pharmaceuticals reports Q1 results1
07.08.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial Results603Revenues increased 18% compared to same period last yearU.S. revenue increased 57% compared to same period last yearNet loss per share decreased 43% compared to same period last year BOULDER, COLORADO...
► Artikel lesen
17.06.Sonoma Pharmaceuticals GAAP EPS of -$0.48, revenue of $3.75M5
17.06.Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results585Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss improved...
► Artikel lesen
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1